Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Berlin – page 64

1 770 clinical trials in Berlin, Germany across 17 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Berlin at a glance
1 770
clinical trials
  • Research sites17
Type of trial
Recruitment status
Quick filters

1 770 trials in Berlin

Open in trial search

Efficacy of efgartigimod alfa as first‑line add‑on to IV methylprednisolone for moderate‑to‑severe attacks in patients with demyelinating diseases

Not yet recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Medizinische Hochschule Hannover

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Muscular dystrophy

Not yet recruiting

Long-Term Safety and Efficacy of Oral Ribitol in Participants with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I/R9)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Ribitol
  • Sponsor:ML Bio Solutions Inc.

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Vertex Pharmaceuticals Inc.

Systemic candida

Not yet recruiting

Shortening treatment duration in adults with uncomplicated candidemia: caspofungin acetate versus saline and sodium lactate placebo

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Caspofungin Acetate
  • Sponsor:University Of Cologne

Systemic scleroderma

Not yet recruiting

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Septic shock+1

Not yet recruiting

Angiotensin II in Children and Adolescents With Refractory Hypotension in Distributive Shock

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:ANGIOTENSIN II

Autoimmune myositis

Not yet recruiting

A study to evaluate the safety and effectiveness of CABA-201, fludarabine, and cyclophosphamide in patients with active inflammatory myopathy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Caba-201
  • Sponsor:Cabaletta Bio Inc.

Borderline personality disorder

Not yet recruiting

A study to evaluate the effectiveness and safety of AP707 in patients with borderline personality disorder.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Adezunap
  • Sponsor:Apurano Pharmaceuticals GmbH

B precursor type acute leukaemia

Not yet recruiting

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Novartis Pharma AG

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Pfizer Inc.

Acute lymphocytic leukaemia+1

Not yet recruiting

A study to evaluate the safety and effectiveness of subcutaneous blinatumomab in adults and adolescents with relapsed, refractory, or minimal residual disease positive B-cell precursor acute lymphoblastic leukemia.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Amgen Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Berlin

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on various cancer treatments, including studies of metastatic prostate cancer, colorectal cancer, and innovative approaches for breast cancer treatment.

  • Prostate Cancer Therapeutics
  • Colorectal Cancer Treatment
  • Early-Stage Breast Cancer
  • Bladder Cancer Interventions

Novel combination therapies and targeted treatments are being evaluated to improve patient outcomes across multiple cancer types.

02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting various viral infections, including studies on respiratory syncytial virus, cytomegalovirus, and herpes zoster.

  • RSV Vaccine Development
  • CMV Prevention
  • Yellow Fever Protection
  • Herpes Virus Management

These trials aim to enhance immune response and provide long-term protection against serious viral infections.

03 Chronic Conditions

Innovative treatments for various chronic conditions, including autoimmune dementia, hypertriglyceridemia, and studies in transplant medicine.

  • Neurological Disorders
  • Metabolic Conditions
  • Organ Transplantation
  • Women's Health

Research focuses on developing targeted therapies and improving treatment outcomes for long-term conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.